Skip to main content

Table 3b. Characteristics of Host Modifiers and Immune-Based Therapy Under Evaluation for Treatment of COVID-19

Last Updated: June 11, 2020

  • The information in this table is derived from data on the use of these drugs and biologic products for FDA-approved indications or from investigational trials; it is supplemented with data from patients with COVID-19 where available.
  • The effective dosing of these agents for management of COVID-19 is unknown. Therefore, the doses listed below are primarily derived from FDA-approved indications or from clinical trials investigating therapies for COVID-19.
  • There are limited or no data on dose modifications for patients with organ failure or those who require extracorporeal devices. Please refer to product labels, when available.
  • Treatment-related AEs in patients with COVID-19 are not well defined; the validity of extrapolation between patient populations (i.e., FDA-approved use vs. COVID-19 use) is unknown, especially in critically ill patients. Reported AEs of these drugs that are associated with long-term therapy (i.e., months to years) are not included in this table because treatment for COVID-19 is not long term. Please refer to product labels, when available.
  • There are currently not enough data to determine whether certain medications can be safely coadministered with treatment for COVID-19. When using concomitant medications with similar toxicity profiles, consider additional safety monitoring.
  • The potential additive, antagonistic, or synergistic effects and the safety of combination therapies for treatment of COVID-19 are unknown. Clinicians are encouraged to report AEs to the FDA MedWatch program.
  • For drug interaction information, please refer to product labeling and visit the Liverpool COVID-19 Drug Interactions website.
  • For information on drugs that prolong the QTc interval, please visit CredibleMeds.org.
Table 3b. Characteristics of Immune-Based Therapy Under Evaluation for Treatment of COVID-19
Table 3b. Characteristics of Immune-Based Therapy Under Evaluation for Treatment of COVID-19

References

  1. Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion. 2012;52(1):160-165. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21762464.
  2. Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090-1095. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25278221.
  3. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-alfa2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother. 2015;70(7):2129-2132. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25900158.
  4. Peginterferon alfa-2a (PEGASYS) [package insert]. Food and Drug Administration. 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103964s5270lbl.pdf. Accessed: April 8, 2020.
  5. Arabi YM, Asiri AY, Assiri AM, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-beta1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020;21(1):8. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31900204.
  6. Interferon beta-1b (BETASERON) [package insert]. Food and Drug Administration. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103471s5195lbl.pdf. Accessed: April 8, 2020.
  7. Interferon beta-1a (REBIF) [package insert]. Food and Drug Administration. 2019.Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103780s5204lbl.pdf. Accessed: April 8, 2020.
  8. Sarilumab (KEVZARA) [package insert]. Food and Drug Administration. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761037s001lbl.pdf. Accessed: April 8, 2020.
  9. Regeneron and Sanofi provide update on U.S. phase 2/3 adaptive-designed trial of KEVZARA® (sarilumab) in hospitalized COVID-19 patients [press release]. 2020. Available at: https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive.
  10. Siltuximab (SYLVANT) [package insert]. Food and Drug Administration. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125496s018lbl.pdf. Accessed: May 5, 2020.
  11. Tocilizumab (ACTEMRA) [package insert]. Food and Drug Administration. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125276s127,125472s040lbl.pdf. Accessed: April 8, 2020.
  12. Baricitinib (OLUMIANT) [package insert]. Food and Drug Administration. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207924s001lbl.pdf. Accessed: April 8, 2020.